But the bloc’s move to insulate itself from growing drug shortages threatens to exacerbate the increasing scarcity of medicines facing the NHS, posing serious problems for doctors.
As a result of Brexit the UK is now isolated from this system, so our drug supplies could be at risk in the future,” said Dr Andrew Hill, an expert on the pharmaceutical trade.
Britain is experiencing a record level of drug shortages, with more than 100 – including treatments for cancer, type 2 diabetes and motor neurone disease – scarce or impossible to obtain.
Mark Dayan, the Brexit programme lead at the Nuffield Trust health thinktank, said the EU’s decision to act as a buying cartel could seriously disadvantage Britain.
The EU is also considering offering drug companies incentives to build new manufacturing plants as part of its response to global scarcities caused by events such as the Russia-Ukraine war.
But the Association of the British Pharmaceutical Industry, which represents drug companies in the UK, denied the EU’s moves would necessarily worsen shortages in Britain.
The original article contains 852 words, the summary contains 173 words. Saved 80%. I’m a bot and I’m open source!
This is the best summary I could come up with:
But the bloc’s move to insulate itself from growing drug shortages threatens to exacerbate the increasing scarcity of medicines facing the NHS, posing serious problems for doctors.
As a result of Brexit the UK is now isolated from this system, so our drug supplies could be at risk in the future,” said Dr Andrew Hill, an expert on the pharmaceutical trade.
Britain is experiencing a record level of drug shortages, with more than 100 – including treatments for cancer, type 2 diabetes and motor neurone disease – scarce or impossible to obtain.
Mark Dayan, the Brexit programme lead at the Nuffield Trust health thinktank, said the EU’s decision to act as a buying cartel could seriously disadvantage Britain.
The EU is also considering offering drug companies incentives to build new manufacturing plants as part of its response to global scarcities caused by events such as the Russia-Ukraine war.
But the Association of the British Pharmaceutical Industry, which represents drug companies in the UK, denied the EU’s moves would necessarily worsen shortages in Britain.
The original article contains 852 words, the summary contains 173 words. Saved 80%. I’m a bot and I’m open source!